Osteochondral lesion of talus
Osteochondral lesion of talus- Terms
Historically, many terms have been used.
Osteochondral dissecans (OCD)
Transchondral talar fracture
Osteochondral talar fracture
Osteochondral lesion of talus (OLT)
Introduced in 1994
Osteochondral lesion of talus - Incidence
2011 epidemiologic study in US military
27 per 100,000 patient-years
More common than previously considered
Incidence of bilateral lesions
Approximately 10%
Medial lesion is more common than lateral lesion
Osteochondral lesion of talus - Clinical presentation
Prolonged pain
Recurrent ankle swelling
Weakness or giving way symptoms
Continued subjective instability
Mechanical symptoms
Catching
Locking
Clicking
P/Ex
Tenderness at the joint level
In patents with chronic ankle pain, high index of suspicion is needed!!
Osteochondral lesion of talus - Etiology
Trauma
Widely believed as a major etiology in the pathogenesis
Up to 76%
Single event of macro-trauma (sprains or fractures)
Repetitive micro-trauma
Non-trauma
Metabolic abnormalities
Vasculopathy
Osteonecrosis or ischemia of talar dome
Osteochondral lesion of talus - Pathophysiology
Primary dysfunction of the subchondral bone
Localized osteonecrosis
Disease progression
Subchondral cysts
Overlying chondromalacia
Osteochondral fragments
Loose bodies
Pain
Is a result of stimulation of highly innervated subchondral bone under cartilage defect
Osteochondral lesion of talus - Imaging and Classification
Berndt and Harty (1959)
First staging system
Radiographic findings
Osteochondral lesion of talus - Imaging and Classification
MRI classification system (1989)
Surgical treatment strategy
Indication
Refractory to 3 to 6 months of non-operative treatment
Categorized as
Cartilage-Repair Strategies
Cartilage-Regeneration Strategies
Cartilage-Replacement Strategies
Surgical treatment strategy
Cartilage-Repair Strategies
Bone marrow stimulation (BMS)
Retrograde drilling
Cartilage-Regeneration Strategies
Autologous chondrocyte implantation (ACI)
Matrix-induced autologous chondrocyte implantation (MACI)
Platelet-rich plasma and bone marrow-derived cell transplantation
Cartilage-Replacement Strategies
Osteochondral autograft transfer (OAT)
Osteochondral allografting
Surgical treatment strategy
Cartilage-Repair Strategies
Bone marrow stimulation (BMS)
Retrograde drilling
Cartilage-Regeneration Strategies
Autologous chondrocyte implantation (ACI)
Matrix-induced autologous chondrocyte implantation (MACI)
Platelet-rich plasma and bone marrow-derived cell transplantation
Cartilage-Replacement Strategies
Osteochondral autograft transfer (OAT)
Osteochondral allografting
BMS
Microfracture
Bone marrow progenitor cells from subchondral bone
Fibrocartilage (mainly composed of type I collagen)
Structurally inferior to native hyaline cartilage (type II collagen)
Reliable clinical outcomes in reducing pain and increasing function
Arthroscopic
Success rate ≈ 85%
Relatively inexpensive
Low morbidity
Prognostic factors
Size
Location
Containment
BMS
Size
< 150 mm^2
Location and containment
Contained (nonshoulder) VS Uncontained (shoulder)
Uncontained lesions have worse outcome